EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Catalent's Enterprise Value is $16,134 Mil.
Catalent's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $99 Mil. Therefore, Catalent's EV-to-FCF for today is 162.97.
The historical rank and industry rank for Catalent's EV-to-FCF or its related term are showing as below:
CTLT'
s EV-to-FCF Range Over the Past 10 Years
Min: -644.24 Med: 37.46 Max: 903.13
Current: 162.97
During the past 13 years, the highest EV-to-FCF of Catalent was 903.13. The lowest was -644.24. And the median was 37.46.
CTLT's EV-to-FCF is not ranked
in the Drug Manufacturers industry.
Industry Median: 25.5
vs CTLT: 162.97
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for Catalent's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Catalent's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catalent's EV-to-FCF Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Catalent's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Catalent's EV-to-FCF falls into.
Catalent's current Enterprise Value is $16,134 Mil.
Catalent's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Catalent (NYSE:CTLT) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Catalent's share price for today is $63.48.
Catalent's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.270.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Catalent EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Catalent's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CTLT has been successfully added to your 